NMI 870

Drug Profile

NMI 870

Latest Information Update: 18 Mar 2008

Price : $50

At a glance

  • Originator NitroMed
  • Class
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Erectile dysfunction; Female sexual dysfunction

Most Recent Events

  • 06 Mar 2008 Discontinued - Phase-II for Female sexual dysfunction in USA (unspecified route)
  • 06 Mar 2008 Discontinued - Phase-II for Erectile dysfunction in USA (unspecified route)
  • 06 Mar 2008 NitroMed's nitric oxide-enhancing technologies are available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top